ENGLEWOOD, Colo., March 9, 2022 /PRNewswire/ -- Ampio
Pharmaceuticals, Inc. (NYSE American: AMPE), a
biopharmaceutical company focused on the advancement of
immunomodulatory therapies for the treatment of pain resulting from
osteoarthritis, will attend the 34th Annual ROTH
Conference, which is being held in Laguna
Niguel, California from March 13-15,
2022.
Ampio Chairman and CEO, Mike
Martino, will be participating in one-on-one meetings, with
investors and analysts, throughout the duration of the conference.
Mr. Martino will also be participating in a fireside chat on
Tuesday, March 15 at 4:30pm ET (1:30pm
PT). The discussion will be moderated by Jonathan Aschoff, PhD, Senior Research Analyst,
Biotechnology, at Roth Capital Partners.
For additional information or to schedule a one-on-one meeting
with Ampio management, please contact
oneononerequests@roth.com.
To learn more and submit a registration request,
visit https://ibn.fm/ROTH2022Registration.
About 34th Annual ROTH Conference
The Annual Roth Conference is one of the largest in the nation
for small-cap companies. Roth combines company presentations,
Q&A sessions and management 1-on-1 meetings. Their
award-winning Research Team identifies distinguished presenting
companies across broad sectors, including consumer, energy,
healthcare, industrial growth, metals & mining, sustainability,
services, technology and more. Following the success of the
previous years, our Roth Conference, with close to 550
participating companies and over 5,100 attendees, will feature
presentations from public and private companies in a variety of
sectors.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company
primarily focused on the advancement of immunology-based therapies
to treat prevalent inflammatory conditions for which there are
limited treatment options. Ampio's lead drug, Ampion™, is backed by
an extensive patent portfolio with intellectual property protection
extending through 2037 and may be eligible for 12-year FDA market
exclusivity upon approval as a novel biologic under the Biologics
Price Competition and Innovation Act (BPCIA).
Forward Looking Statements
Ampio's statements in this press release that are not historical
fact, and that relate to future plans or events, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by the use of words such as "believe,"
"expect," "plan," "anticipate," and similar expressions. These
forward-looking statements include statements regarding Ampio's
expectations with respect to Ampion and its classification, as
well as those associated with regulatory approvals and other FDA
decisions, clinical trials and decisions and changes in business
conditions and similar events and the likelihood and timing of
Ampion's approval as a novel biologic under the BPCIA, all of which
are inherently subject to various risks and uncertainties. The
risks and uncertainties involved include those detailed from time
to time in Ampio's filings with the Securities and Exchange
Commission, including without limitation, under Ampio's Annual
Report on Form 10-K and other documents filed with the Securities
and Exchange Commission. Ampio undertakes no obligation to revise
or update these forward-looking statements, whether as a result of
new information, future events or otherwise.
Investor and Media Contacts:
Tony Russo or Nic Johnson
Russo Partners
info@ampiopharma.com
tony.russo@russopartnersllc.com
nic.johnson@russopartnersllc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ampio-pharmaceuticals-to-participate-at-the-34th-annual-roth-conference-301498769.html
SOURCE Ampio Pharmaceuticals, Inc.